Re
Manager Medical Study Operations
Regeneron Pharmaceuticals
Full-time
Sleepy Hollow, NY
other-general
Posted:
June 10, 2026
Location:
Sleepy Hollow, NY, United States
Job Description
As a Manager, Medical Study Operations you are responsible for all operational aspects of Global Medical Affairs Oncology, including Investigator-Initiated Studies (IIS), Research Collaborations (RC), and Data Transparency requests across multiple products and new molecules. ensuring compliance with applicable standards and regulations.
This position will require you to be on-site 4 days/week at our Sleepy Hollow, NY offices. If eligible, we can offer relocation benefits. We cannot offer a remote work option.
**A typical may include the following:**
• Manage multiple projects/programs, including IIS, Research Collaborations, and Data Transparency, with moderate direction.
• Ensure proposals align with Areas of Interest, are complete, and reviewed by the appropriate governing bodies. Obtain all necessary approvals, including those from the Medical Affairs Review Committee (MARC), Collaborator/Partners, and Senior Management, for both original proposals and amendm...
This position will require you to be on-site 4 days/week at our Sleepy Hollow, NY offices. If eligible, we can offer relocation benefits. We cannot offer a remote work option.
**A typical may include the following:**
• Manage multiple projects/programs, including IIS, Research Collaborations, and Data Transparency, with moderate direction.
• Ensure proposals align with Areas of Interest, are complete, and reviewed by the appropriate governing bodies. Obtain all necessary approvals, including those from the Medical Affairs Review Committee (MARC), Collaborator/Partners, and Senior Management, for both original proposals and amendm...
Apply for this Job
Submit your application for the Manager Medical Study Operations position at Regeneron Pharmaceuticals.
Apply Now Save for LaterJob Overview
Job Type:
Full-time
Location:
Sleepy Hollow, United States
Posted:
June 10, 2026
Deadline:
June 15, 2026